Approaches to Non-Muscle-Invasive Bladder Cancer

被引:30
作者
Slovacek, Hannah [1 ]
Zhuo, Jerry [2 ]
Taylor, Jennifer M. [2 ]
机构
[1] Loyola Univ, Stritch Sch Med, Chicago, IL 60611 USA
[2] Baylor Coll Med, Dept Urol, 7200 Cambridge St,Ste 10B, Houston, TX 77030 USA
关键词
Bladder cancer; Non-muscle-invasive bladder cancer; BCG; Intravesical therapy; Survivorship; BACILLUS-CALMETTE-GUERIN; HYPERTHERMIC INTRAVESICAL CHEMOTHERAPY; TRANSITIONAL-CELL CARCINOMA; MITOMYCIN-C; TRANSURETHRAL RESECTION; UROTHELIAL CANCER; LIGHT CYSTOSCOPY; MANAGEMENT; THERAPY; TRIAL;
D O I
10.1007/s11912-021-01091-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of Review Non-muscle-invasive bladder cancer (NMIBC) is a heterogenous malignancy with high recurrence and progression rates, which necessitate uniform recommendations for diagnosis and management. Herein, we review the literature, with an emphasis on guidelines and contemporary diagnostic techniques and interventions. Recent Findings Guidelines around the world have adopted a schema which risk-stratify cases at diagnosis, to offer evidence-based treatment and surveillance recommendations. Enhanced endoscopic technologies can improve detection of NMIBC and reduce recurrence. The present Bacillus Calmette-Guerin (BCG) shortage in the USA has led to new strategies to prioritize the most high-risk cases. The entity of BCG-unresponsive high-risk NMIBC remains a challenge to manage, with multiple novel treatments under investigation; fortunately, new therapies have been approved, such as immune checkpoint inhibitors, and others are showing tremendous promise. The standardization of NMIBC management, with evolving detection techniques and therapeutics, offers great potential to improve patient outcomes and survivorship.
引用
收藏
页数:11
相关论文
共 70 条
  • [41] The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours
    Humphrey, Peter A.
    Moch, Holger
    Cubilla, Antonio L.
    Ulbright, Thomas M.
    Reuter, Victor E.
    [J]. EUROPEAN UROLOGY, 2016, 70 (01) : 106 - 119
  • [42] Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors
    Kale, Hrishikesh P.
    Carroll, Norman V.
    [J]. CANCER, 2016, 122 (08) : 283 - 289
  • [43] Complications of intravesical therapy for urothelial cancer of the bladder
    Koya, Madhusudan P.
    Simon, Michael A.
    Soloway, Mark S.
    [J]. JOURNAL OF UROLOGY, 2006, 175 (06) : 2004 - 2010
  • [44] Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C
    Lenis, Andrew T.
    Asanad, Kian
    Blaibel, Maher
    Donin, Nicholas M.
    Chamie, Karim
    [J]. BMC UROLOGY, 2018, 18
  • [45] An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer
    Malmstrom, Per-Uno
    Sylvester, Richard J.
    Crawford, David E.
    Friedrich, Martin
    Krege, Susanne
    Rintala, Erkki
    Solsona, Eduardo
    Di Stasi, Savino M.
    Witjes, J. Alfred
    [J]. EUROPEAN UROLOGY, 2009, 56 (02) : 247 - 256
  • [46] Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
    Massard, Christophe
    Gordon, Michael S.
    Sharma, Sunil
    Rafii, Saeed
    Wainberg, Zev A.
    Luke, Jason
    Curiel, Tyler J.
    Colon-Otero, Gerardo
    Hamid, Omid
    Sanborn, Rachel E.
    O'Donnell, Peter H.
    Drakaki, Alexandra
    Tan, Winston
    Kurland, John F.
    Rebelatto, Marlon C.
    Jin, Xiaoping
    Blake-Haskins, John A.
    Gupta, Ashok
    Segal, Neil H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26) : 3119 - +
  • [47] Financial Toxicity of Having Bladder Cancer
    Messing, Edward M.
    [J]. BLADDER CANCER, 2018, 4 (03) : 351 - 352
  • [48] Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence SWOG S0337 Randomized Clinical Trial
    Messing, Edward M.
    Tangen, Catherine M.
    Lerner, Seth P.
    Sahasrabudhe, Deepak M.
    Koppie, Theresa M.
    Wood, David P., Jr.
    Mack, Philip C.
    Svatek, Robert S.
    Evans, Christopher P.
    Hafez, Haled S.
    Culkin, Daniel J.
    Brand, Timothy C.
    Karsh, Lawrence I.
    Holzbeierlein, Jeffrey M.
    Wilson, Shandra S.
    Wu, Guan
    Plets, Melissa
    Vogelzang, Nicholas J.
    Thompson, Ian M., Jr.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (18): : 1880 - 1888
  • [49] Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories
    Mossanen, Matthew
    Wang, Ye
    Szymaniak, Julie
    Tan, Wei Shen
    Huynh, Melissa J.
    Preston, Mark A.
    Quoc-Dien Trinh
    Sonpavde, Guru
    Kibel, Adam S.
    Chang, Steven L.
    [J]. WORLD JOURNAL OF UROLOGY, 2019, 37 (10) : 2059 - 2065
  • [50] Unusual complication after immediate postoperative intravesical mitomycin C instillation
    Nieuwenhuijzen, JA
    Bex, A
    Horenblas, S
    [J]. EUROPEAN UROLOGY, 2003, 43 (06) : 711 - 712